Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Psilocybe cubensis
Psychedelic mushroom used in Aztec and Mazatec sacred healing ceremonies for millennia. Now in FDA breakthrough therapy status for depression and PTSD. Legal status varies.
Psilocybin (Psilocybe cubensis) is a naturally occurring psychedelic compound historically used in Mesoamerican sacred ceremonies and now under FDA breakthrough therapy designation for treatment-resistant depression and PTSD. Its primary active metabolites, psilocin and baeocystin, act as serotonin 5-HT2A receptor agonists, inducing altered states of consciousness and neuroplasticity. Modern research focuses on its antidepressant, anti-addictive, and existential distress-relieving properties, though evidence remains limited to pilot trials and anecdotal reports.
Psilocybin is rapidly dephosphorylated to psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, with additional affinity for 5-HT1A, 5-HT2C, and 5-HT3 receptors. Activation of 5-HT2A receptors on cortical pyramidal neurons increases glutamate release, leading to enhanced neuroplasticity, dendritic spine growth, and disruption of default mode network connectivity. Psilocin also modulates dopamine D2 and adrenergic receptors, contributing to its psychoactive and potential therapeutic effects. The compound's ability to promote synaptic remodeling and reduce fear-related amygdala reactivity underlies its proposed antidepressant and anti-anxiety mechanisms.
Psychedelic mushroom used in Aztec and Mazatec sacred healing ceremonies for millennia. Now in FDA breakthrough therapy status for depression and PTSD. Legal status varies.
Psilocybin (Psilocybe cubensis) is a naturally occurring psychedelic compound historically used in Mesoamerican sacred ceremonies and now under FDA breakthrough therapy designation for treatment-resistant depression and PTSD. Its primary active metabolites, psilocin and baeocystin, act as serotonin 5-HT2A receptor agonists, inducing altered states of consciousness and neuroplasticity. Modern research focuses on its antidepressant, anti-addictive, and existential distress-relieving properties, though evidence remains limited to pilot trials and anecdotal reports.
Psilocybin is rapidly dephosphorylated to psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, with additional affinity for 5-HT1A, 5-HT2C, and 5-HT3 receptors. Activation of 5-HT2A receptors on cortical pyramidal neurons increases glutamate release, leading to enhanced neuroplasticity, dendritic spine growth, and disruption of default mode network connectivity. Psilocin also modulates dopamine D2 and adrenergic receptors, contributing to its psychoactive and potential therapeutic effects. The compound's ability to promote synaptic remodeling and reduce fear-related amygdala reactivity underlies its proposed antidepressant and anti-anxiety mechanisms.